Regeneron shares fall after FDA rejects high-dose eye disease treatment

Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."

from Health and Science https://ift.tt/QVMXofI
https://ift.tt/wynWK79
https://ift.tt/HYfWBLJ